Expression of CD68 and Fas Ligand in Colon Mucosa of Patients with Inflammatory Bowel Disease as Prognostic Markers of Cancerogenesis

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


As it is known, colon carcinogenesis is associated with the inflammatory bowel disease (IBD). Colorectal cancer (CRC) being observed in 5.5-13.5 % of patients with ulcerative colitis (UC) and in 0.4-0.8 % of patients with Crohn disease (CD). The gut mucosa of patients with CD, but not with UC, as well as the stroma of CRC have elevated numbers of CD68(+) macrophages. It is known also that the expression of Fas Ligand (FasL), representing another branch of immunoreactivity, in the lesions of CRC and UC but not of CD is upregulated. The fact that enterocyte apoptosis is increased in lesions of CD and lymphocytes in UC are resistant to Fas-mediated apoptosis can be the keypoint for understanding the hypothesis [17], suggesting that cells express FasL and are able to kill Fas-expressing activated lymphocytes and escape rejection by the immune system, which can be the basis for differences in association of UC and CD with CRC. The aim of this study was to evaluate the number of CD68(+) macrophages and to analyze FasL expression in colon mucosa of patients with UC, CD and CRC in order to assess its value for prognosis of CRC. Expression of CD68 and FasL was analyzed immunohistochemically in the samples of colon mucosa taken from the affected areas of 4 patients with UC, 6 patients with CD and 10 patients with CRC. In addition in 7 CRC patients the samples taken from unaffected areas were analyzed. We find average expression of FasL in both unaffected and affected areas of CRC patients was higher than in CD patients (p = 0.04, p = 0.00). Average expression of FasL in affected areas of CRC patients was higher (p = 0.02) than in UC patients and the same (p = 0.23) as in unaffected areas of CRC patients. The revealed associations support the possibility to use expression of CD68 and FasL as prognostic markers for transformation of IBD to CRC.

Full Text

Restricted Access

About the authors

Andrey V Santimov

St Petersburg State Pediatric Medical University

Author for correspondence.
Email: a.santimoff@gmail.com

Russian Federation MD, Research Fellow, Department of Hospital Pediatrics

Andrey V Kolobov

Saint Petersburg State University

Email: pathandrey@rambler.ru

Russian Federation MD, PhD, Associate Professor, Department of Pathology

Vadim E Karev

Research Institute of Children Infection Diseases FMBA of Russia

Email: karev@fromru.com

Russian Federation MD, PhD, Head of the Lab of Pathomorphology

Oksana L Kolobova

St Petersburg State Pediatric Medical University

Email: aksjutakolobova@rambler.ru

Russian Federation MD, PhD, Associate Professor, Department of Hospital Pediatrics

Mikhail M Kostik

St Petersburg State Pediatric Medical University

Email: kost-mikhail@yandex.ru

Russian Federation MD, PhD, Associate Professor, Department of Hospital Pediatrics

Margarita F Dubko

St Petersburg State Pediatric Medical University

Email: mf-dubko@yandex.ru

Russian Federation MD, PhD, Associate Professor, Department of Hospital Pediatrics

Olga V Kalashnikova

St Petersburg State Pediatric Medical University

Email: koira7@yandex.ru

Russian Federation MD, PhD, Associate Professor, Department of Hospital Pediatrics

Vera V Masalova

St Petersburg State Pediatric Medical University

Email: masalova.vera@gmail.com

Russian Federation Assistant Professor, Department of Hospital Pediatrics

Lyudmila S Snegireva

St Petersburg State Pediatric Medical University

Email: l.s.snegireva@mail.ru

Russian Federation MD, Department of Pediatrics No 3

Natalia L Volkova

St Petersburg State Pediatric Medical University

Email: volkovanatalia.dr@yandex.ru

Russian Federation MD, Head of Department. Department of Gastroenterology

Andrey A Khvatov

St Petersburg State Pediatric Medical University

Email: andrey_hvatov@mail.ru

Russian Federation Assistant Professor, Department of Oncology.

Margarita B Belogurova

St Petersburg State Pediatric Medical University

Email: deton.hospital31@inbox.ru

Russian Federation MD, PhD, Dr Med Sci, Professor, Head of the Department of Oncology

Vyacheslav G Chasnyk

St Petersburg State Pediatric Medical University

Email: chasnyk@gmail.com

Russian Federation MD, PhD, Dr Med Sci, Professor, Head of the Department of Hospital Pediatrics

References

  1. Залетова Н.К., Чухловин А.Б., Третьяк А.Т., и др. Генетические факторы, влияющие на эффективность терапии глюкокортикоидами при хронических воспалительных заболеваниях кишечника у детей // Педиатр. — 2015. — Т. 4. — № 3. — С. 91–97. [Zaletova NK, Chukhlovin A B, Tretjak AT, et al. Genetic factors modifying response to glucocorticoid treatment in chronic pediatric inflammatory bowel diseases. Pediatr (St Petersburg). 2015;4(3):91-97 (In Russ).]
  2. Маркова Д.О., Ревнова М.О., Насыров Р.А. Цитомегаловирусная инфекция у больных с воспалительными заболеваниями кишечника // Педиатр. — 2013. — Т. 4. — № 1. — С. 95–99. [Markova DO, Revnova MO, Nasyrov RA. Cytomegalovirus infection in the patients with in FLammatory bowel disease. Pediatr (St Petersburg). 2013;4 (1):95-99. (In Russ).].
  3. Allen C, Hogg N. Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst. 1987 Mar;78(3):465-70.
  4. Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001 May;120(6):1356-62. doi: 10.1053/gast.2001.24052.
  5. Bell S, Kamm MA. Antibodies to tumour necrosis factor alpha as treatment for Crohn’s disease. Lancet. 2000 Mar 11;355(9207):858-60. doi: 10.1016/S0140-6736(99)00442-0.
  6. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002 Mar;196(3):254-65. doi: 10.1002/path.1027.
  7. Chaput N, Svrcek M, Aupérin A, et al. Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer. 2013 Aug 20;109(4):1013-22. doi: 10.1038/bjc.2013.362. Epub 2013 Jul 18.
  8. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994; 35:950-4. doi: 10.1136/gut.35.7.950.
  9. Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci. 1925;170:220-8. doi: 10.1097/00000441-192508010-00006.
  10. Demetter P, De Vos M, Van Huysse JA, et al. Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis. 2005 Feb;64(2): 321-4. Epub 2004 May 27. doi: 10.1136/ard.2003.018382.
  11. Di Sabatino A, Ciccocioppo R, Luinetti O, et al. Increased enterocyte apoptosis in inflamed areas of Crohn’s disease. Dis Colon Rectum. 2003 Nov;46(11):1498-507. doi: 10.1007/s10350-004-6802-z.
  12. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcera- tive colitis: a meta-analysis. Gut. 2001;48:526-35. doi: 10.1136/gut.48.4.526.
  13. Ekbom A, Helmick C, Zack M, Adami H. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336:357-9. doi: 10.1016/0140-6736(90)91889-I.
  14. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 1993 Mar 15;81(6):1607-13.
  15. Liu S, Russo PA, Baldassano RN, Sullivan KE. CD68 expression is markedly different in Crohn’s disease and the colitis associated with chronic granulomatous disease. Inflamm Bowel Dis. 2009 Aug;15(8):1213-7. doi: 10.1002/ibd. 20890.
  16. Nagata S, Golstein P. The Fas death factor. Science. 1995 Mar 10;267(5203):1449-56. doi: 10.1126/science.7533326.
  17. O’Connell J, Bennett MW, O’Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 1999 Jan; 20(1):46-52. doi: 10.1016/S0167-5699(98)01382-6.
  18. Odze RD. Pathology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:533. doi: 10.1016/j.gtc.2006.07.007.
  19. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984 Dec 20-1985 Jan 2;312(5996):724-9.
  20. Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70.
  21. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004 Jan;4(1):71-8. doi: 10.1038/nrc1256.
  22. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol. 2008 Jan 21;14(3):390-400. doi: 10.3748/wjg. 14.390.
  23. Thyberg J, Graf W, Klingenström P. Intestinal fine structure in Crohn’s disease. Lysosomal inclusions in epithelial cells and macrophages. Virchows Arch A Pathol Anat Histol. 1981;391(2):141-52. doi: 10.1007/BF00437592.
  24. Ueyama H, Kiyohara T, Sawada N, et al. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut. 1998 Jul;43(1):48-55. doi: 10.1136/gut.43.1.48.
  25. Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn’s disease and cancer. N Engl J Med. 1973 Nov 22;289(21):1099-103. doi: 10.1056/NEJM197311222892101.
  26. Zhang W, Ding EX, Wang Q, et al. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol. 2005 Jun 21;11(23):3632-5. doi: 10.3748/wjg.v11.i23.3632.
  27. Zhang Y, Sime W, Juhas M, Sjölander A. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. Eur J Cancer. 2013 Oct;49(15):3320-34. doi: 10.1016/j.ejca.2013.06.005. Epub 2013

Statistics

Views

Abstract - 1869

PDF (Russian) - 228

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2016 Santimov A.V., Kolobov A.V., Karev V.E., Kolobova O.L., Kostik M.M., Dubko M.F., Kalashnikova O.V., Masalova V.V., Snegireva L.S., Volkova N.L., Khvatov A.A., Belogurova M.B., Chasnyk V.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies